Literature DB >> 18841188

Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use.

Desiree L Kunac1, Mira Harrison-Woolrych, Michael V Tatley.   

Abstract

The New Zealand Pharmacovigilance Centre (NZPhvC) is the national centre responsible for monitoring adverse reactions to therapeutic products in New Zealand(NZ). The NZPhvC operates three pharmacovigilance programmes and this article explains how each of these programmes operate, focuses on their strengths and limitations, and looks to the future for medicines safety monitoring in NZ.

Mesh：

Year:  2008        PMID： 18841188

Source DB:  PubMed          Journal:  N Z Med J        ISSN： 0028-8446


  12 in total

1.  Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand.

Authors:  Mira Harrison-Woolrych; Simran Maggo; Ming Tan; Ruth Savage; Janelle Ashton
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

Review 2.  Experiences with adverse drug reaction reporting by patients: an 11-country survey.

Authors:  Florence van Hunsel; Linda Härmark; Shanthi Pal; Sten Olsson; Kees van Grootheest
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

3.  Expectations for feedback in adverse drug reporting by healthcare professionals in the Netherlands.

Authors:  Ingrid Oosterhuis; Florence P A M van Hunsel; Eugène P van Puijenbroek
Journal:  Drug Saf       Date:  2012-03-01       Impact factor: 5.606

4.  Detecting medication errors in the New Zealand pharmacovigilance database: a retrospective analysis.

Authors:  Desireé L Kunac; Michael V Tatley
Journal:  Drug Saf       Date:  2011-01-01       Impact factor: 5.606

5.  Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand.

Authors:  Mira Harrison-Woolrych; Janelle Ashton
Journal:  Drug Saf       Date:  2011-09-01       Impact factor: 5.606

6.  Epistaxis and other haemorrhagic events associated with the smoking cessation medicine varenicline: a case series from two national pharmacovigilance centres.

Authors:  Mira Harrison-Woolrych; Linda Härmark; Ming Tan; Simran Maggo; Kees van Grootheest
Journal:  Eur J Clin Pharmacol       Date:  2012-02-08       Impact factor: 2.953

7.  Memory impairment associated with varenicline: a case series from the New Zealand Intensive Medicines Monitoring Programme.

Authors:  Ming Tan; Mira Harrison-Woolrych
Journal:  Eur J Clin Pharmacol       Date:  2012-12-12       Impact factor: 2.953

8.  Characterization of Statin-Associated Myopathy Case Reports in Thailand Using the Health Product Vigilance Center Database.

Authors:  Pornwalai Boonmuang; Surakit Nathisuwan; Nathorn Chaiyakunapruk; Wimon Suwankesawong; Pattreya Pokhagul; Nattawat Teerawattanapong; Pairin Supsongserm
Journal:  Drug Saf       Date:  2013-09       Impact factor: 5.606

9.  Safety of Artemisinin-Based Combination Therapies in Nigeria: A Cohort Event Monitoring Study.

Authors:  Peter Usman Bassi; Adeline I Osakwe; Ambrose Isah; Comfort Suku; Musa Kalat; Iliya Jalo; Robinson Daniel Wammanda; Chika Ugochukwu; Olubukula Adesina; Eno Etim Nyong; Frank Osungwu; Shanti Pal; Sylvester Chigozie Nwoasu; Magnus Wallberg; David Coulter
Journal:  Drug Saf       Date:  2013-09       Impact factor: 5.606

10.  Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records.

Authors:  Andrew Tomlin; David Reith; Susan Dovey; Murray Tilyard
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.